BPI 2026 has ended. This guide stays up as the record of who was there. Next: BPI 2027, Sep 20–23, 2027 in Boston
Biotech companies at BPI 2026
Sep 22–25, 2026 Boston, MA ~3k attendees Website
49 biotech companies are at BPI 2026 — 71 presentations on the program. Most represented: Ultragenyx (3 on the program), Genetix Biotherapeutics (2 on the program), Third Arc Bio (2 on the program). 16 of them have their own page in this guide. As of Sep 19, 2026.
Process area
Top represented
Showing 1–13 of 49 organizations
| Organization | BPI 2026 Attendance |
|---|---|
Ultragenyx Novato, California | |
Develops and commercializes therapies for rare and ultra-rare genetic diseases, including AAV gene therapies. | Talk Thu Sep 24 12:00pm–12:30pm Talk Thu Sep 24 4:30pm–5:30pm Panel Fri Sep 25 9:00am–10:00am |
GB Genetix Biotherapeutics Somerville, Massachusetts | |
Gene therapy company, formerly bluebird bio, with marketed lentiviral gene therapies for sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy. | Chair Thu Sep 24 9:20am–9:30am Talk Thu Sep 24 11:45am–12:30pm Talk Thu Sep 24 4:30pm–5:30pm Talk Fri Sep 25 12:40pm–1:20pm |
Develops multifunctional antibody therapeutics, including bispecific T cell engagers. | Talk Wed Sep 23 2:30pm–3:00pm Talk Fri Sep 25 12:40pm–1:20pm Talk Fri Sep 25 3:00pm–3:30pm |
AskBio Research Triangle Park, North Carolina | |
Gene therapy developer, a Bayer subsidiary, working on AAV-based treatments. | Talk Thu Sep 24 10:00am–10:30am Talk Thu Sep 24 2:45pm–3:15pm |
Prime Medicine Cambridge, Massachusetts | |
Biotechnology company developing gene editing therapies based on prime editing, delivered with technologies such as RNA-lipid nanoparticles. | Talk Wed Sep 23 1:00pm–1:45pm From Bench to BLA: Automation and AI-Accelerated Potency Assay Validation Digital Biomanufacturing & AICell & Gene Therapy |
Rocket Pharmaceuticals Cranbury, New Jersey | |
Develops lentiviral and AAV gene therapies for rare childhood disorders. | Panel Fri Sep 25 9:00am–10:00am Talk Fri Sep 25 12:40pm–1:20pm |
SB Siren Biotechnology San Francisco, California | |
Develops AAV-based immuno-gene therapies for cancer, including high grade gliomas. | Talk Fri Sep 25 10:00am–10:30am Talk Fri Sep 25 11:55am–12:15pm |
Solid Biosciences Charlestown, Massachusetts | |
Develops gene therapies for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy. | Keynote Thu Sep 24 9:00am–10:00am |
NB NurExone Biologic | |
Biotechnology company developing exosome-based regenerative therapies and drug delivery, initially for spinal cord and nerve injury. | |
Opthea Melbourne, Australia | |
Biopharmaceutical company developing biologic therapies for retinal diseases. | Talk Tue Sep 22 1:00pm–2:00pm Analytical & Quality CMC & Manufacturing Strategy Panel Tue Sep 22 3:00pm–3:45pm Chair Wed Sep 23 8:55am–9:00am Chair Wed Sep 23 1:55pm–2:00pm |
Aspen Neuroscience San Diego, California | |
Develops autologous iPSC-derived neuron replacement therapy for Parkinson's disease. | Talk Wed Sep 23 5:00pm–5:45pm |
Drug developer working on therapies for chronic hepatitis B. | Talk Fri Sep 25 2:00pm–2:30pm Talk Fri Sep 25 3:00pm–3:30pm |
Disc Medicine Watertown, Massachusetts | |
Clinical-stage developer of therapies for serious hematologic diseases. | Talk Tue Sep 22 9:00am–9:45am Introduction To Upstream Manufacturing Upstream & Cell Culture Panel Tue Sep 22 3:00pm–3:45pm |
Find buyers from biotech companies
Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse BPI 2026 by
Organization type
Process area
Exhibit hall
Everyone
Not affiliated with or endorsed by the BioProcess International Conference & Exhibition or its organizers. Submit a correction